Apheon, a pan-European private equity investor, is pleased to announce a further investment in its portfolio company Ortivity (“Ortivity” or the “Company”), Germany’s leading outpatient orthopaedic care platform. The contemplated transaction provides a partial exit for existing Ortivity shareholders while bringing onboard Unigestion, a leading private equity firm focused on the mid-market, and selected new Apheon investors, thereby reinforcing Apheon’s overall exposure to the Company. The approximate EUR 200 million capital injection marks the successful completion of a targeted partner search. Through its private equity funds, Unigestion acquires a significant minority stake in Ortivity, while Apheon remains the lead investor.

Founded in 2022 by a group of leading physicians, Dr. med. Reinhard Wichels and Apheon, Ortivity has over the past four years developed rapidly into one of Germany’s most prominent outpatient healthcare platforms. The Company operates over 100 sites across three regional clusters in Germany, offering a full spectrum of orthopaedic services, including diagnostics, anaesthesia, surgery, prevention, and aftercare. Ortivity’s physician partnership model and emphasis on clinical excellence have positioned the Group as a trusted provider and builder of modern outpatient infrastructure. The Company is equally owned by physicians and capital providers.

To facilitate and further drive the ambitious growth plans, Apheon ran a targeted search to bring onboard a new financial partner. Through its private equity funds, Unigestion’s additional capital will support Ortivity’s ongoing investments in Germany, prioritizing the enhancement of its integrated, physician-led care model. The transaction marks a significant milestone for the Company as it enters its next phase of growth with an expanded investor base. Apheon and Unigestion have plans to further grow the Company within the existing regional clusters, and to establish new clusters, with the aim to transition Germany’s orthopaedic market towards a more modern, outpatient model.

Nils Lüssem, Partner at Apheon, and Sebastian Walter, Director at Apheon, commented: “We are pleased to welcome Unigestion as a trusted partner. During our search, Unigestion distinguished itself as collaborative, experienced, entrepreneurial and committed to long-term growth – we are delighted to have found such a partner. Since its founding by Apheon and leading physicians, Ortivity has quickly evolved into a leading provider of orthopaedic outpatient care in Germany. Partnering with Unigestion and other selected investors will ensure we have the necessary stable capital to sustain our growth and continue investing in top-quality patient care.”

Philipp Scheier, Partner at Unigestion, commented: “We have been very impressed by Ortivity’s development since its inception in 2022. Its rapid growth is a strong testament to the hard work of the Company’s physicians, management team and Apheon, who have established a leading, high-quality and patient-centred provider of orthopaedic outpatient care solutions. I am looking forward to working together with Ortivity and Apheon to support the next chapter of this unique success story.”

Dr. Andreas Hartung, current Co-CEO, commented “What we have built over the past four years is truly unique and Unigestion realised this right from the start of our partner search.” Dr. med. Michael Thorwarth, newly joined Co-CEO of Ortivity, commented: “I am delighted that the start of my tenure as CEO coincides with the strengthening of the capital base of Ortivity. This marks a significant milestone as we continue to build a powerful network dedicated to innovation in musculoskeletal care. I was drawn to Ortivity by its forward-thinking vision — the seamless integration of prevention, diagnostics, and both conservative and surgical therapies. I look forward to working closely with our orthopaedic and neurosurgical specialists, as well as our dedicated practice teams, to further develop this model. Together, we aim to set new standards in treatment quality and patient-centred service, delivering measurable benefits to those we serve.”

Markus Schneppenheim, Head of the Ortivity Medical Board, practicing physician at the OGPaedicum and co-founder of Ortivity, commented: “Ortivity is the market leader in modern outpatient orthopaedic solutions in Germany. We will now accelerate the expansion of existing clusters and enable the dynamic transfer of concepts to other regions. We are very pleased to continue our collaboration with Apheon and remain fully committed to the joint project.”

Dr. med. Reinhard Wichels, physician, investor and co-founder of Ortivity: “It has been an exciting journey so far. Ortivity has not only become the largest orthopaedic outpatient platform in Germany, but also a visible thought leader on how physician networks can contribute to closing gaps in access and quality of care delivery.”

The transaction is subject to customary regulatory approvals. Houlihan Lokey acted as the exclusive financial advisor to Apheon. Renzenbrink & Partner acted as legal advisors to Apheon.

About Apheon
Apheon is a pan‑European mid‑market private equity firm managing more than €3 billion in assets from select global institutional investors and families. Known for a “patient and friendly capital” approach, Apheon partners with entrepreneurs and management teams, offering industrial expertise to prepare companies for future growth. Through its European presence, the firm serves as a gateway into Europe for companies in the mid-market. Since its founding in 2005, Apheon has raised more than €3.5 billion in capital, invested in ~40 companies across Europe and completed ~200 add-on acquisitions for a total aggregate transaction value in excess of €7 billion. Apheon’s current portfolio consists of 21 companies across its target sectors, representing ~€3 billion sales and more than 20,000 employees. Apheon is advised by Apheon Advisors which has offices in Brussels, Milan, Madrid, Paris, Munich and Amsterdam. For more information, visit www.apheon.com.

About Unigestion Private Equity
Unigestion S.A. manages €12 billion in private equity assets. Its award-winning team offers four key private equity strategies focused on secondaries, directs, emerging managers and climate impact. The team invests in the leaders of tomorrow, selecting exciting, hard-to-access companies with resilient profiles across five themes – supply chain efficiency, resilient infrastructure, future of work, healthcare performance and consumer evolution. Unigestion Private Equity believes that better and more consistent investment decisions can be made by harnessing the power of mind and machine and has applied its proprietary AI technology – PEpper – to private equity investments since 2020. The firm is also at the forefront of ESG investing, having launched its first environmental private equity fund in 2010. For more information, please visit www.unigestion.com.

About Ortivity
Ortivity is Germany’s leading integrated outpatient care platform for orthopaedic services. Built around a physician-led model, the Company operates over 100 medical centres across Germany, offering a full continuum of orthopaedic care. Ortivity has demonstrated consistent growth through a combination of strategic acquisitions and organic development.

+++

Apheon
John Mansvelt, COO, Apheon
jm@apheon.com
T: +32 2 213 60 90

Natalia Yek, Head of Investor Relations, Apheon
ny@apheon.com
T: +32 2 213 60 90

As of August 2025, six highly regarded aesthetic clinics have come together under one name: Leading Aesthetics Group.

This newly formed group represents a significant step forward in the Dutch aesthetic medicine landscape. Each clinic brings a strong local presence, a loyal client base, and a reputation for medical quality and innovation. Together, they form a platform with nationwide coverage and the shared ambition to deliver high-end, doctor-led aesthetic care centred on long-term outcomes, safety, and trust.

The Clinics
• Arthur Ludlage, Cosmetische Kliniek – Haarlem
• Amstelzijde Kliniek – Amstelveen / Amsterdam
• ClausHoltz – Amsterdam
• Gooische Rimpels – Hilversum
• Van Rosmalen Kliniek – Rotterdam / The Hague / Nijmegen
• Haarkliniek De Kroon – Breda

All clinics will continue to operate under their own established names, retaining their individual identity and local reputation. Leading Aesthetics Group will serve as the overarching organisation, providing strategic direction, shared resources and a unified vision for growth. With nine locations across densely populated areas in the Netherlands, the group ensures strong regional coverage and accessibility.

A doctor-led platform with long-term focus.
Leading Aesthetics Group is built on a shared belief in high-quality, minimally invasive treatments with a medical, personalised, and future-oriented approach.
The platform’s core treatments include injectables, advanced skin and laser therapies, and hair transplant and restoration procedures. Treatments are exclusively performed by experienced medical experts.
“Our clients aren’t looking for a single quick fix, but for a treatment plan that evolves with their needs, now and in the future,” says Nicole van Riessen-Verschure, CEO of Leading Aesthetics Group.
“It is that long-term mindset, and the trust we build along the way, that connects every clinic in our group.”
“Our founders each bring over 20 years of pioneering expertise, not just in delivering exceptional results, but in redefining what aesthetic medicine can be. Their vision sets a new standard where innovation, integrity, and long-term care converge to shape the future of high-end cosmetic treatments.” CMO (Chief medical officer) of Leading Aesthetics Group, Annemarie van Rosmalen.

Supported by Bencis – built to grow
The group is backed by investment firm Bencis which has deep expertise in scaling multi-site healthcare businesses. A clear buy-and-build strategy is in place, focused on sustainable growth and consolidation in a fragmented market, both in the Netherlands and across Europe.
Leading Aesthetics Group benefits from medical excellence, operational synergies and a shared vision for continuous innovation. Each clinic retains its unique strengths while benefiting from a unified, scalable platform.

Looking ahead
This is the beginning of a new chapter.
The group is well positioned to lead in a fast-developing market, combining medical leadership, premium positioning, and strong client relationships.
Clients will immediately benefit from the collective expertise, integrated services and ongoing innovation across the platform.
With a clear ambition, a strong foundation and a doctor-led model, Leading Aesthetics Group is set to shape the future of high-end aesthetic care in the Netherlands and beyond.